- Summit Therapeutics (SMMT, Financial) is set to release its Q1 2025 financial results on May 1, 2025, with an earnings call to follow.
- Analysts have set an average target price of $31.00, signaling a potential 33.56% upside.
- The current brokerage recommendation for SMMT is "Outperform," based on a 1.7 average rating.
Summit Therapeutics (SMMT) will unveil its first-quarter 2025 financial results on May 1, 2025, at 4:30 pm ET. Investors should note that this biopharmaceutical leader will also provide an essential operational update during an earnings call, which will be accessible via a live webcast on their official website.
Wall Street Analysts Forecast
Summit Therapeutics Inc (SMMT, Financial) has garnered attention from analysts who have provided a one-year average price target of $31.00. This projection, based on assessments from 9 analysts, includes high and low estimates ranging from $44.00 to $5.00. Given the current stock price of $23.21, this average target indicates a promising upside potential of 33.56%. For a detailed breakdown of these estimates, visit the Summit Therapeutics Inc (SMMT) Forecast page.
In terms of brokerage recommendations, Summit Therapeutics Inc (SMMT, Financial) boasts an "Outperform" status, with an average recommendation score of 1.7 provided by 10 brokerage firms. The rating scale spans from 1 to 5, where 1 signifies a Strong Buy and 5 signifies a Sell. This rating suggests a generally favorable outlook among analysts.
However, when considering GuruFocus metrics, the estimated GF Value for Summit Therapeutics Inc (SMMT, Financial) in one year is calculated to be $0.39. This estimate implies a significant downside of 98.32% from the current price of $23.21. The GF Value is derived from historical trading multiples and future business performance predictions. To explore more in-depth data, please refer to the Summit Therapeutics Inc (SMMT) Summary page.
